JPWO2020181145A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181145A5 JPWO2020181145A5 JP2021552717A JP2021552717A JPWO2020181145A5 JP WO2020181145 A5 JPWO2020181145 A5 JP WO2020181145A5 JP 2021552717 A JP2021552717 A JP 2021552717A JP 2021552717 A JP2021552717 A JP 2021552717A JP WO2020181145 A5 JPWO2020181145 A5 JP WO2020181145A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- protein composition
- heterodimeric protein
- inactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- 239000000203 mixture Substances 0.000 claims description 91
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 239000000178 monomer Substances 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 5
- 108090000625 Cathepsin K Proteins 0.000 claims description 5
- 102000004171 Cathepsin K Human genes 0.000 claims description 5
- 108090000613 Cathepsin S Proteins 0.000 claims description 5
- 102100035654 Cathepsin S Human genes 0.000 claims description 5
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 5
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 5
- 108010091175 Matriptase Proteins 0.000 claims description 5
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 4
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 4
- -1 Trop2 Proteins 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814159P | 2019-03-05 | 2019-03-05 | |
| US201962814210P | 2019-03-05 | 2019-03-05 | |
| US62/814,210 | 2019-03-05 | ||
| US62/814,159 | 2019-03-05 | ||
| US201962814744P | 2019-03-06 | 2019-03-06 | |
| US62/814,744 | 2019-03-06 | ||
| US201962826523P | 2019-03-29 | 2019-03-29 | |
| US62/826,523 | 2019-03-29 | ||
| PCT/US2020/021276 WO2020181145A1 (en) | 2019-03-05 | 2020-03-05 | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524337A JP2022524337A (ja) | 2022-05-02 |
| JPWO2020181145A5 true JPWO2020181145A5 (enExample) | 2023-03-13 |
Family
ID=70058513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552717A Ceased JP2022524337A (ja) | 2019-03-05 | 2020-03-05 | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220144949A1 (enExample) |
| EP (1) | EP3934761A1 (enExample) |
| JP (1) | JP2022524337A (enExample) |
| CN (1) | CN114173876A (enExample) |
| AU (1) | AU2020231391A1 (enExample) |
| CA (1) | CA3132651A1 (enExample) |
| WO (1) | WO2020181145A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2022125576A1 (en) | 2020-12-09 | 2022-06-16 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| EP4416185A4 (en) * | 2021-10-15 | 2025-09-03 | Harpoon Therapeutics Inc | CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| DE10231109A1 (de) | 2002-07-10 | 2004-01-22 | Daimlerchrysler Ag | Abgasturbine |
| AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| WO2017087789A1 (en) * | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| MX2018010824A (es) * | 2016-03-08 | 2019-05-15 | Maverick Therapeutics Inc | Proteinas de union inducibles y metodos de uso. |
| EP3589662A4 (en) * | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| IL302613B2 (en) * | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| CN111315773A (zh) | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| US20210309756A1 (en) * | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2020
- 2020-03-05 EP EP20716051.6A patent/EP3934761A1/en active Pending
- 2020-03-05 US US17/435,931 patent/US20220144949A1/en not_active Abandoned
- 2020-03-05 WO PCT/US2020/021276 patent/WO2020181145A1/en not_active Ceased
- 2020-03-05 JP JP2021552717A patent/JP2022524337A/ja not_active Ceased
- 2020-03-05 CA CA3132651A patent/CA3132651A1/en active Pending
- 2020-03-05 CN CN202080033827.6A patent/CN114173876A/zh active Pending
- 2020-03-05 AU AU2020231391A patent/AU2020231391A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| AU2018280683B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| KR102771251B1 (ko) | 제약된 조건적으로 활성화된 결합 단백질 | |
| CN114390938B (zh) | 受约束的条件性活化的结合蛋白 | |
| JP2020124209A5 (enExample) | ||
| IL261432B1 (en) | Induced binding proteins and methods of use | |
| JP2020534811A (ja) | Ｆｃ領域を含有する条件的に活性化された結合部分 | |
| JP2022524337A (ja) | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 | |
| RS61399B1 (sr) | Vezne belančevine slične antitelu sa dva varijabilna regiona koje imaju ukrštenu orijentaciju veznog regiona | |
| GB2518221A (en) | Tetravalent antigen-binding protein molecule | |
| JP6927618B2 (ja) | 多重特異性タンパク質薬物およびそのライブラリー、ならびに製造方法と使用 | |
| JP2017534296A5 (enExample) | ||
| JPWO2020181145A5 (enExample) | ||
| Kim et al. | Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength | |
| CN116419925A (zh) | 受限的条件激活的结合蛋白 | |
| JPWO2020181140A5 (enExample) | ||
| WO2022261124A1 (en) | Peptides comprising n-formyl-halogenated methionine residues and engineered antibody-peptide conjugates thereof | |
| JPWO2022040128A5 (enExample) | ||
| CN116554340A (zh) | 新型长效化和高活性且更安全的抗体构建体 | |
| RU2024106011A (ru) | Белки, которые разобщают опосредуемую t-клетками противоопухолевую цитотоксичность и высвобождение провоспалительных цитокинов | |
| TW202342521A (zh) | 條件性雙特異性結合蛋白 | |
| JP2011079758A (ja) | タンパク質と微粒子との複合体及びその製造方法 | |
| EA041608B1 (ru) | Гетеродимерный полиспецифичный формат антител | |
| Valldorf | Multivalent display of functional biomacromolecules: a modular approach |